Allogene Therapeutics Stock (NASDAQ: ALLO) stock price, news, charts, stock research, profile.
Open | - |
Close | - |
Volume / Avg. | 2.00 / 2.50M |
Day Range | - - - |
52 Wk Range | 2.01 - 5.78 |
Market Cap | $585.51M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 53 |
Short Interest | 26.21% |
Days to Cover | 22.96 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Allogene Therapeutics (NASDAQ:ALLO) through any online brokerage.
Other companies in Allogene Therapeutics’s space includes: Humacyte (NASDAQ:HUMA), 4D Molecular Therapeutics (NASDAQ:FDMT), Celcuity (NASDAQ:CELC), Altimmune (NASDAQ:ALT) and Pharming (NASDAQ:PHAR).
Allogene Therapeutics has a consensus price target of $13.42.
The stock price for Allogene Therapeutics (NASDAQ: ALLO) is $2.8 last updated September 20, 2024 at 7:27 PM EDT.
There are no upcoming dividends for Allogene Therapeutics.
Allogene Therapeutics’s Q3 earnings are confirmed for Thursday, October 31, 2024.
There is no upcoming split for Allogene Therapeutics.
Allogene Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.